Sightline Wealth Advisors LLC Has $341,000 Holdings in Pfizer Inc. (NYSE:PFE)

Sightline Wealth Advisors LLC lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 21.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 11,768 shares of the biopharmaceutical company’s stock after selling 3,132 shares during the period. Sightline Wealth Advisors LLC’s holdings in Pfizer were worth $341,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of PFE. Olistico Wealth LLC acquired a new position in Pfizer in the second quarter valued at $25,000. MFA Wealth Advisors LLC acquired a new position in Pfizer in the second quarter valued at $29,000. Quarry LP acquired a new position in Pfizer in the second quarter valued at $31,000. Trivant Custom Portfolio Group LLC increased its stake in Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 600 shares in the last quarter. Finally, Financial Connections Group Inc. bought a new stake in Pfizer in the second quarter valued at $34,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the subject of several research analyst reports. Wells Fargo & Company lifted their price target on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Wednesday, October 9th. UBS Group lifted their price target on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Sanford C. Bernstein initiated coverage on shares of Pfizer in a research note on Thursday. They issued a “market perform” rating and a $32.00 price target for the company. Finally, Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.91.

Pfizer Stock Down 0.9 %

Pfizer stock traded down $0.27 during midday trading on Monday, hitting $28.95. 11,038,042 shares of the stock were exchanged, compared to its average volume of 36,978,707. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $31.54. The stock has a market capitalization of $164.05 billion, a price-to-earnings ratio of -483.67, a price-to-earnings-growth ratio of 1.02 and a beta of 0.67. The business’s 50-day moving average price is $29.07 and its 200-day moving average price is $28.45. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. During the same period in the previous year, the company earned $0.67 earnings per share. The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. On average, research analysts expect that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 5.80%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently -2,800.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.